Results 1 to 10 of about 35,211 (119)

Everolimus and de novo malignancies after liver transplantation: A nationwide emulated trial using real-world data [PDF]

JHEP Reports
Background & Aims: Liver transplantation (LT) is associated with an increased risk of de novo malignancies (DNMs). Everolimus is an mTOR inhibitor with immunosuppressive and potentially antineoplastic properties.
Ilias Kounis, Tri-Long Nguyen, Christophe Desterke, Nathalie Goutte, Didier Samuel, Daniel Azoulay, Eric Vibert, Faouzi Saliba, Audrey Coilly, Paul Landais, Cyrille Féray   +10 more
doaj   +2 more sources

Experience of a Single Center in Treating Multiple Manifestations of Tuberous Sclerosis Complex with Everolimus [PDF]

Annals of Child Neurology, 2019
Purpose The aim of this study was to evaluate the efficacy and tolerability of everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, for the treatment of tuberous sclerosis complex (TSC) manifestations.
Hyunji Ahn, Mi-Sun Yum, Han Na Jang, Cheryn Song, Tae-Sung Ko   +4 more
doaj   +1 more source

First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature

European Journal of Medical Research, 2023
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) used in both transplantation and cancer treatment (breast, renal and neuroendocrine).
Eduard Fort-Casamartina, Carme Muñoz-Sanchez, Raul Francisco Rigo-Bonnin, Pamela Maria del Valle-Celiz, Núria Gonzalo-Diego, Sara Otero-Torres, Carmen Bleda-Perez, Judith Prats-Jimenez, Sandra Fontanals-Martínez   +8 more
doaj   +1 more source

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Breast Cancer Research, 2021
Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus.
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, John Crown, Javier Cortés   +19 more
doaj   +1 more source

In Vitro and In Vivo Evaluation of Synergistic Effects of Everolimus in Combination with Antifungal Agents on Exophiala dermatitidis

Microbiology Spectrum, 2023
To investigate the combined function of the novel oral mTOR inhibitor, everolimus, with antifungal agents and their potential mechanisms against Exophiala dermatitidis, the CLSI microliquid-based dilution method M38-A2, chequerboard technique, and disk ...
Gengpei Jia, Jing Hu, Lihua Tan, Longting Li, Lujuan Gao, Yi Sun   +5 more
doaj   +1 more source

Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics

Clinical and Translational Science, 2022
Everolimus has recently been used to prevent graft rejection in liver transplantation and reduces the incidence of kidney dysfunction caused by calcineurin inhibitors.
Kotaro Itohara, Ikuko Yano, Shunsaku Nakagawa, Mitsuhiro Sugimoto, Machiko Hirai, Atsushi Yonezawa, Satoshi Imai, Takayuki Nakagawa, Daiki Hira, Takashi Ito, Koichiro Hata, Etsuro Hatano, Tomohiro Terada, Kazuo Matsubara   +13 more
doaj   +1 more source

Hemorrhagic Colitis Caused by Everolimus in a Patient with Nonfunctional Pancreatic Neuroendocrine Neoplasms: A Case Report

Medicina, 2022
A 60-year-old woman was diagnosed with nonfunctional pancreatic neuroendocrine neoplasm with multiple liver metastases and was administered everolimus. Due to persistent epigastric pain and diarrhea, a colonoscopy was performed on the 14th day after the ...
Noriyuki Arakawa, Atsushi Irisawa, Kazuyuki Ishida, Takuya Tsunoda, Yoshiko Yamaguchi, Akane Yamabe, Makoto Eizuka, Shunzo Tokioka, Hiroto Wakabayashi   +8 more
doaj   +1 more source

Effect of the Combination of Everolimus and Mesenchymal Stromal Cells on Regulatory T Cells Levels and in a Liver Transplant Rejection Model in Rats

Frontiers in Immunology, 2022
IntroductionMesenchymal stromal cells (MSCs) have particular properties that are of interest in organ transplantation, including the expansion of regulatory T cells (Tregs), a key factor in transplant tolerance induction.
Morgan Vandermeulen, Morgan Vandermeulen, Morgan Vandermeulen, Pauline Erpicum, Pauline Erpicum, Noella Bletard, Laurence Poma, François Jouret, François Jouret, Olivier Detry, Olivier Detry   +10 more
doaj   +1 more source

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. [PDF]

PLoS ONE, 2018
INTRODUCTION:The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo for the treatment of renal angiomyolipomas associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM).
John J Bissler, Norio Nonomura, Klemens Budde, Bernard A Zonnenberg, Michael Fischereder, Maurizio Voi, Anne-Laure Louveau, Fabian Herbst, E Martina Bebin, Paolo Curatolo, Andrea Zonta, Elena Belousova   +11 more
doaj   +1 more source

ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma

Molecular Therapy: Nucleic Acids, 2019
The clinical efficiency of everolimus, an mammalian target of rapamycin (mTOR) inhibitor, is palliative as sequential or second-line therapy for renal cell carcinoma (RCC). However, the limited response of everolimus in RCC remains uncertain.
Yun Zou, Wenzhi Li, Juan Zhou, Jin Zhang, Yiran Huang, Zhong Wang   +5 more
doaj   +1 more source